TQH3906 vs WD-890

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

TQH3906

Developed by Sino Biopharmaceutical

Phase 3 in PsoriasisSmall molecule (oral TYK2 inhibitor)
Partial signal

NCT06542614 · Phase 2 · completed

This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.

Next expected readout: September 2027 · NCT07724366 (registry estimate)

Reported efficacy

Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)

Result source: NCT06542614

WD-890

Developed by Ningbo/Zhejiang Wenda Pharma Technology Co.

Phase 3 in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT07672561 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTQH3906WD-890
PASI 75—Trial running · NCT07724366—Trial running · NCT07672561
PASI 90—Trial running · NCT07724366—Trial running · NCT07672561
PASI 100—Trial running · NCT07724366—Trial running · NCT07672561
sPGA 0/1—Trial running · NCT07724366—Trial running · NCT07672561
DLQI, change—Trial running · NCT07724366—Trial running · NCT07672561

PASI 75

TQH3906
—Trial running · NCT07724366
WD-890
—Trial running · NCT07672561

PASI 90

TQH3906
—Trial running · NCT07724366
WD-890
—Trial running · NCT07672561

PASI 100

TQH3906
—Trial running · NCT07724366
WD-890
—Trial running · NCT07672561

sPGA 0/1

TQH3906
—Trial running · NCT07724366
WD-890
—Trial running · NCT07672561

DLQI, change

TQH3906
—Trial running · NCT07724366
WD-890
—Trial running · NCT07672561
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

WD-890: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQH3906
At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks NCT06542614 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: TQH3906's landscape · WD-890's landscape